7OIX image
Deposition Date 2021-05-12
Release Date 2022-06-01
Last Version Date 2024-10-16
Entry Detail
PDB ID:
7OIX
Title:
Structure of thermostable human MFSD2A in complex with thermostable human Sync2
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.60 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Syncytin-2
Gene (Uniprot):ERVFRD-1
Chain IDs:A
Chain Length:538
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Isoform 2 of Sodium-dependent lysophosphatidylcholine symporter 1
Gene (Uniprot):MFSD2A
Chain IDs:B
Chain Length:530
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural insights into the lysophospholipid brain uptake mechanism and its inhibition by syncytin-2.
Nat.Struct.Mol.Biol. 29 604 612 (2022)
PMID: 35710838 DOI: 10.1038/s41594-022-00786-8

Abstact

Brain development and function require uptake of essential omega-3 fatty acids in the form of lysophosphatidylcholine via major-facilitator superfamily transporter MFSD2A, a potential pharmaceutical target to modulate blood-brain barrier (BBB) permeability. MFSD2A is also the receptor of endogenous retroviral envelope syncytin-2 (SYNC2) in human placenta, where it mediates cell-cell fusion and formation of the maternal-fetal interface. Here, we report a cryo-electron microscopy structure of the human MFSD2A-SYNC2 complex that reveals a large hydrophobic cavity in the transporter C-terminal domain to occlude long aliphatic chains. The transporter architecture suggests an alternating-access transport mechanism for lipid substrates in mammalian MFS transporters. SYNC2 establishes an extensive binding interface with MFSD2A, and a SYNC2-soluble fragment acts as a long-sought-after inhibitor of MFSD2A transport. Our work uncovers molecular mechanisms important to brain and placenta development and function, and SYNC2-mediated inhibition of MFSD2A transport suggests strategies to aid delivery of therapeutic macromolecules across the BBB.

Legend

Protein

Chemical

Disease

Primary Citation of related structures